Protection of Primary Dopaminergic Midbrain Neurons Through Impact of Small Molecules Using Virtual Screening of GPR139 Supported by Molecular Dynamic Simulation and Systems Biology

Interdiscip Sci. 2019 Jun;11(2):247-257. doi: 10.1007/s12539-019-00334-x. Epub 2019 Jun 8.

Abstract

Introduction: GPCR share a common structural feature, i.e., the presence of seven trans-membrane helices having three intracellular and three extracellular loops. The carboxyl terminal is intracellular whereas amino terminal is extracellular. Various conformational changes are observed in structure of GPCR during the binding with ligand, coupling with G protein and interaction with other proteins. In Rhodopsin class of GPCR the basic structure of GPCR is resolved by X-ray crystallography. Ligand acts as an extracellular stimulus for GPCRs to bring physiological changes in organisms. GPR139 has been found to have effective physiological role in primary dopaminergic midbrain neurons and in central nervous system. Recent reports suggested that the ligand of GPR139 protein inhibits the growth of primary dopaminergic midbrain neurons in central nervous system. These discoveries indicated the potential involvement and influence of GPR139 protein in central nervous system METHOD: Therefore, we used multi-approach analysis to investigate the role of GPR139 in the molecular mechanisms of central nervous system. In silico screening was performed to study compound 1 binding with GPR139 protein in their predicted three-dimensional structures. Compound 1 was subjected to molecular dynamics (MD) simulation and stability analysis.

Results: The results of MD analysis suggested that the loop region in GPR139 protein structure could affect its binding with drugs. Finally, we cross-validated the predicted compound 1 through systems biology approach. Our results suggested that GPR139 might play an important role in primary dopaminergic midbrain neurons therapy.

Keywords: 7TM; GPCR; GPR139; MD simulation; Primary dopaminergic midbrain neurons.

MeSH terms

  • Binding Sites
  • Diabetes Mellitus, Type 2 / metabolism
  • Dopaminergic Neurons / cytology*
  • Dopaminergic Neurons / drug effects
  • Drug Evaluation, Preclinical*
  • Humans
  • Mesencephalon / cytology*
  • Molecular Docking Simulation
  • Molecular Dynamics Simulation*
  • Neuroprotection* / drug effects
  • Parkinson Disease / metabolism
  • Protein Domains
  • Receptors, G-Protein-Coupled / chemistry
  • Receptors, G-Protein-Coupled / metabolism*
  • Signal Transduction / drug effects
  • Small Molecule Libraries / chemistry
  • Small Molecule Libraries / pharmacology*
  • Structure-Activity Relationship
  • Systems Biology*
  • Time Factors

Substances

  • Receptors, G-Protein-Coupled
  • Small Molecule Libraries